Covid-19
FDA | No useful monoclonal antibody treatments left against new COVID-19 variants.
7 Dec, 2022 | 14:31h | UTCFDA: No Useful Monoclonal Antibody Treatments Left Against New COVID-19 Variants – HealthDay
Related: Study shows Omicron sublineage BQ.1.1 is resistant to all monoclonal antibodies.
M-A | Higher vs. lower dose corticosteroids for severe to critical COVID-19.
6 Dec, 2022 | 14:00h | UTC
Case-control study | Effectiveness of COVID-19 vaccines against infection and mortality in children in Argentina.
2 Dec, 2022 | 14:36h | UTC
Cross-sectional study | Overweight women may be at increased risk of long Covid.
2 Dec, 2022 | 14:33h | UTCCommentaries:
Overweight women may be at highest risk of long COVID – new research – The Conversation
M-A | Efficacy and safety of COVID-19 inactivated vaccine.
1 Dec, 2022 | 14:00h | UTCEfficacy and safety of COVID-19 inactivated vaccine: A meta-analysis – Frontiers in Medicine
RCT | Medical masks vs. N95 respirators for preventing COVID-19 among health care workers.
30 Nov, 2022 | 13:52h | UTC
Commentary on Twitter
A randomized trial of medical masks vs N95s in health care workers to prevent Covid https://t.co/CSJkFLE15z
—It's woefully underpowered but ruled out a doubling of hazard for use of medical masks
—In 3 of the 4 countries there was less risk with N95s (p=NS) pic.twitter.com/B7iBvT1J9B— Eric Topol (@EricTopol) November 28, 2022
ACP Guidance | Outpatient treatment of confirmed COVID-19.
30 Nov, 2022 | 13:54h | UTCCommentary: New ACP living practice points, mortality data on COVID-19 – ACP Internist
Cohort Study | Acute and postacute sequelae associated with SARS-CoV-2 reinfection.
30 Nov, 2022 | 13:42h | UTCAcute and postacute sequelae associated with SARS-CoV-2 reinfection – Nature Medicine
News Release: Repeat COVID-19 infections increase risk of organ failure, death – Washington University School of Medicine
Commentary: SARS-CoV-2 Reinfection Ups Risks for Death, Hospitalization – HealthDay
Study shows Omicron sublineage BQ.1.1 is resistant to all monoclonal antibodies.
29 Nov, 2022 | 14:16h | UTCOmicron sublineage BQ.1.1 resistance to monoclonal antibodies – The Lancet Infectious Diseases
Commentaries:
Omicron variant BQ.1.1 found to be resistant to all monoclonal antibody treatments – MedicalXpress
Related: BQ.1 and BQ.1.1 are now the dominant COVID variants. What does that mean? – MedicalXpress
Commentary on Twitter
The BQ.1.1 variant, as compared with many of the other new variants, is resistant to all clinically used monoclonal antibodies.
BQ.1/BQ.1.1 are now the dominant variants in the United Stateshttps://t.co/PCFPSGF2uy @TheLancetInfDis pic.twitter.com/dHucxoGokC— Eric Topol (@EricTopol) November 19, 2022
Cohort Study | Impact of the trimester of diagnosis on COVID-19 disease progression in pregnancy.
29 Nov, 2022 | 14:18h | UTCExamining the impact of trimester of diagnosis on COVID-19 disease progression in pregnancy – American Journal of Obstetrics & Gynecology MFM (free for a limited period)
News Release: Risk of severe COVID-19 symptoms remains throughout pregnancy, study finds – UT Southwestern Medical Center
Commentary on Twitter
Aug 20: Examining impact of trimester of diagnosis on #COVID19 disease progression in #pregnancy: Moderate, severe, or critical illness develops in almost 10% of pregnant patients; frequency of disease progression does not differ by trimester @ajogmfm https://t.co/hnF8QxmE2k!
— All Source Pregnancy (@PregnancyAll) August 20, 2022
Review | Care of the seriously ill patient with SARS-CoV-2.
24 Nov, 2022 | 13:26h | UTCCare of the Seriously Ill Patient with SARS-CoV-2 – Medical Clinics of North America
A multinational Delphi consensus to end the COVID-19 public health threat.
4 Nov, 2022 | 14:01h | UTCA multinational Delphi consensus to end the COVID-19 public health threat – Nature
Cohort Study | Covid-19 vaccine effectiveness among children and adolescents in Qatar.
4 Nov, 2022 | 13:51h | UTC
Commentary on Twitter
The 10-µg dose of BNT162b2 led to modest, rapidly waning protection against Covid-19 in children 5 to 11 years old. The 30-µg dose in adolescents gave greater, more durable protection; more so in 12-to-14-year-olds than in 15-to-17-year-olds. https://t.co/ddcqiR8jvO pic.twitter.com/M8oSFYoFlw
— NEJM (@NEJM) November 2, 2022
Brief Review | Close collaboration between pathologists and intensivists to understand (not just) coronavirus disease.
4 Nov, 2022 | 13:37h | UTC
Commentary on Twitter
Pathologists & intensivists collaborating to understand (not just) #COVID19
➡️ facing an unknown entity: challenge in #ICU
➡️ lightening pathophysiological shadow: demand for autopsies
➡️ formalizing interdisciplinary exchange to optimize outcome#FOAMcc
🗞️https://t.co/0a48Vontzn pic.twitter.com/K9zTl5b8vp— Intensive Care Medicine (@yourICM) November 2, 2022
M-A | Effect of pulmonary rehabilitation in dyspnea, exercise capacity, fatigue, and quality of life in patients with COVID-19.
3 Nov, 2022 | 14:09h | UTC
Comparative risk of thrombosis with thrombocytopenia or thromboembolic events with different covid-19 vaccines.
3 Nov, 2022 | 14:10h | UTC
RCT | Ivermectin does not improve time to recovery in outpatients with mild to moderate COVID-19.
24 Oct, 2022 | 14:14h | UTCCommentary: Ivermectin doesn’t speed time to recovery from nonsevere COVID – CIDRAP
Commentary on Twitter
Study findings do not support the use of #ivermectin in outpatients with mild to moderate #COVID19. https://t.co/do8zbVkeLK #Research
— JAMA (@JAMA_current) October 21, 2022
RCT | Evaluation of mRNA-1273 vaccine in children 6 months to 5 years of age.
20 Oct, 2022 | 12:35h | UTC
Commentary on Twitter
Randomized, placebo-controlled trial of the 2-dose @moderna_tx vaccine in children 6 months to 5 years, during Omicron. Safe in ~4,800 kids; good immune response; efficacy vs infections 👇https://t.co/DkLXAQQaeZ @NEJM pic.twitter.com/ettWOnDGQf
— Eric Topol (@EricTopol) October 19, 2022
Myocarditis after BNT162b2 vaccination in Israeli adolescents.
20 Oct, 2022 | 12:34h | UTCMyocarditis after BNT162b2 Vaccination in Israeli Adolescents – New England Journal of Medicine
Commentary on Twitter
Among Israeli adolescents between 12 and 15 years of age who received the BNT162b2 vaccine, 9 cases of mild myocarditis were observed, mainly after the second dose. https://t.co/OatYqN4IPD pic.twitter.com/c96d1o7wnt
— NEJM (@NEJM) October 19, 2022
Pooled analysis of cohort studies | Severe COVID-19 outcomes after full vaccination of primary schedule and initial boosters.
19 Oct, 2022 | 14:28h | UTCCommentaries:
Prioritisation of COVID-19 boosters in the omicron era – The Lancet
COVID booster halved severe illness, but some groups still at higher risk – CIDRAP
RCT | Efficacy of BCG vaccination in reducing the incidence and severity of COVID-19 in a high-risk population.
19 Oct, 2022 | 14:26h | UTC
Case-control study | Odds of hospitalization for COVID-19 after 3 vs. 2 doses of mRNA vaccine by time since booster dose.
19 Oct, 2022 | 14:27h | UTC
Incidence of myocarditis/pericarditis following mRNA COVID-19 vaccination among children and younger adults in the US.
13 Oct, 2022 | 13:51h | UTC
Commentary on Twitter (thread – click for more)
Let me me perfectly clear about the evidence for myocarditis after mRNA vaccines
1. There is a notable increased incidence, age 12-39, males, with each dose (Table)https://t.co/XXQbyeLiSP pic.twitter.com/wLTZT3fppy— Eric Topol (@EricTopol) October 12, 2022
Commentary on Twitter
Let me me perfectly clear about the evidence for myocarditis after mRNA vaccines
1. There is a notable increased incidence, age 12-39, males, with each dose (Table)https://t.co/XXQbyeLiSP pic.twitter.com/wLTZT3fppy— Eric Topol (@EricTopol) October 12, 2022
Estimated global proportions of persistent fatigue, cognitive, and respiratory symptoms following symptomatic COVID-19.
11 Oct, 2022 | 13:39h | UTCCommentaries:
Women And Hospitalized Patients More Prone To Long Covid, Study Finds – Forbes
Nearly two-thirds of long COVID patients are female, global study finds – UPI
Commentary on Twitter
A new @IHME_UW modeling study on #LongCovid based upon 1.2 million people with Covid from 22 countrieshttps://t.co/evMcFVJ2vU @JAMA_current pic.twitter.com/qt1bgHkaVV
— Eric Topol (@EricTopol) October 10, 2022
RCT | High-flow nasal cannula oxygen did not reduce mortality in patients with respiratory failure due to COVID-19.
28 Sep, 2022 | 13:51h | UTCEffect of High-Flow Nasal Cannula Oxygen vs Standard Oxygen Therapy on Mortality in Patients With Respiratory Failure Due to COVID-19: The SOHO-COVID Randomized Clinical Trial – JAMA (link to abstract – $ for full-text)
Commentary: High-Flow Oxygen Fails to Reduce Mortality due to COVID-19 Respiratory Failure – HCP Live